Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)

S. Morken; S. W. Langer; A. Sundlov; S. Detlefsen; M. Krogh; E. Tabaksblat; G. O. Hjortland; J. B. Svensson; J. Assmus; A. Couvelard; A. Perren; H. Sorbye

doi:10.1111/jne.13108

Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)

S. Morken, S. W. Langer, A. Sundlov, S. Detlefsen, M. Krogh, E. Tabaksblat, G. O. Hjortland, J. B. Svensson, J. Assmus, A. Couvelard, A. Perren, H. Sorbye

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Journal of Neuroendocrinology
Vol/bind	34
Udgave nummer	S1
Sider (fra-til)	181-181
Antal sider	1
ISSN	0953-8194
DOI	https://doi.org/10.1111/jne.13108
Status	Udgivet - 2022
Begivenhed	19th Annual ENETS Conference on the Diagnosis and Treatment of Neuroendocrine Tumor Disease - Baltimore, Spanien Varighed: 10 mar. 2022 → 11 mar. 2022

Konference

Konference	19th Annual ENETS Conference on the Diagnosis and Treatment of Neuroendocrine Tumor Disease
Land/Område	Spanien
By	Baltimore
Periode	10/03/2022 → 11/03/2022

Adgang til dokumentet

10.1111/jne.13108

Citationsformater

Morken, S., Langer, S. W., Sundlov, A., Detlefsen, S., Krogh, M., Tabaksblat, E., Hjortland, G. O., Svensson, J. B., Assmus, J., Couvelard, A., Perren, A., & Sorbye, H. (2022). Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC). Journal of Neuroendocrinology, 34(S1), 181-181. https://doi.org/10.1111/jne.13108

Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC). / Morken, S.; Langer, S. W.; Sundlov, A. et al.
I: Journal of Neuroendocrinology, Bind 34, Nr. S1, 2022, s. 181-181.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Morken, S, Langer, SW, Sundlov, A, Detlefsen, S, Krogh, M, Tabaksblat, E, Hjortland, GO, Svensson, JB, Assmus, J, Couvelard, A, Perren, A & Sorbye, H 2022, 'Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)', Journal of Neuroendocrinology, bind 34, nr. S1, s. 181-181. https://doi.org/10.1111/jne.13108

@article{8cd0f54a9d014b6c84f2ae70b81df492,

title = "Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)",

keywords = "neuroendocrine neoplasm, neuroendocrine carcinoma, high-grade gastroenteropancreatic, everolimus, temozolomide",

author = "S. Morken and Langer, {S. W.} and A. Sundlov and S. Detlefsen and M. Krogh and E. Tabaksblat and Hjortland, {G. O.} and Svensson, {J. B.} and J. Assmus and A. Couvelard and A. Perren and H. Sorbye",

year = "2022",

doi = "10.1111/jne.13108",

language = "English",

volume = "34",

pages = "181--181",

journal = "Journal of Neuroendocrinology",

issn = "0953-8194",

publisher = "Wiley-Blackwell",

number = "S1",

note = "19th Annual ENETS Conference on the Diagnosis and Treatment of Neuroendocrine Tumor Disease ; Conference date: 10-03-2022 Through 11-03-2022",

}

TY - ABST

T1 - Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)

AU - Morken, S.

AU - Langer, S. W.

AU - Sundlov, A.

AU - Detlefsen, S.

AU - Krogh, M.

AU - Tabaksblat, E.

AU - Hjortland, G. O.

AU - Svensson, J. B.

AU - Assmus, J.

AU - Couvelard, A.

AU - Perren, A.

AU - Sorbye, H.

PY - 2022

Y1 - 2022

KW - neuroendocrine neoplasm

KW - neuroendocrine carcinoma

KW - high-grade gastroenteropancreatic

KW - everolimus

KW - temozolomide

U2 - 10.1111/jne.13108

DO - 10.1111/jne.13108

M3 - Conference abstract in journal

SN - 0953-8194

VL - 34

SP - 181

EP - 181

JO - Journal of Neuroendocrinology

JF - Journal of Neuroendocrinology

IS - S1

T2 - 19th Annual ENETS Conference on the Diagnosis and Treatment of Neuroendocrine Tumor Disease

Y2 - 10 March 2022 through 11 March 2022

ER -